ATAI
AtaiBeckley Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-07 | HERSHBERG ROBERT |
Director |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026. The stock option is fully vested. |
Stock Option
|
51,142 |
| 2026-07-07 | HERSHBERG ROBERT |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.90 to $5.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
Common Stock
|
100,000 |
| 2026-07-07 | HERSHBERG ROBERT |
Director |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026. The stock option is fully vested. |
Stock Option
|
48,858 |
| 2026-07-07 | HERSHBERG ROBERT |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026. |
Common Stock
|
51,142 |
| 2026-07-07 | HERSHBERG ROBERT |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026. |
Common Stock
|
48,858 |
| 2026-06-26 | Kochendoerfer Gerd |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The stock option vested (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on December 3, 2025 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Common Stock
|
50,000 |
| 2026-06-26 | Kochendoerfer Gerd |
Chief Operating Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. |
Common Stock
|
50,000 |
| 2026-06-26 | Kochendoerfer Gerd |
Chief Operating Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. The stock option vested (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on December 3, 2025 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
50,000 |
| 2026-06-25 | Craig Kevin James |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
9,528 |
| 2026-06-25 | Craig Kevin James |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. |
Stock Option
|
9,528 |
| 2026-06-25 | Craig Kevin James |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
33,051 |
| 2026-06-25 | Craig Kevin James |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. |
Stock Option
|
33,051 |
| 2026-06-25 | Craig Kevin James |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.50 to $4.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price |
Common Stock
|
42,579 |
| 2026-06-04 | Hoffman John Francis |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | Angermayer Christian |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | Smiley Andrea Heslin |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | Braunstein Scott |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
86,095 |
| 2026-06-04 | JOHNSON SABRINA MARTUCCI |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | HERSHBERG ROBERT |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | Kalali Amir H |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | Fischer Laurent |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-06-04 | Braunstein Scott |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. |
Stock Option
|
121,968 |
| 2026-04-20 | Craig Kevin James |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
27,280 |
| 2026-04-20 | Craig Kevin James |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The stock option vested as to 25% of the underlying shares on January 1, 2025, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. |
Stock Option
|
15,299 |
| 2026-04-20 | Craig Kevin James |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
15,299 |
| 2026-04-20 | Craig Kevin James |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. |
Stock Option
|
27,280 |
| 2026-04-20 | Craig Kevin James |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
42,579 |
| 2026-04-08 | Angermayer Christian |
Director, 10% Owner |
Convert↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired upon exercise of options and held by the Reporting Person. |
Common Stock
|
410,162 |
| 2026-04-08 | Angermayer Christian |
Director, 10% Owner |
Convert↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired upon exercise of options and held by the Reporting Person. |
Common Stock
|
103,000 |
| 2026-04-08 | Angermayer Christian |
Director, 10% Owner |
Convert↓
Filing footnotes — Stock Option (Direct)
The stock option is fully vested and exercisable. |
Stock Option
|
103,000 |
| 2026-04-08 | Angermayer Christian |
Director, 10% Owner |
Convert↓
Filing footnotes — Stock Option (Direct)
The stock option vested with respect to 25% of the shares on January 5, 2025, and will vest with respect to the remaining shares in 36 monthly installments thereafter. |
Stock Option
|
410,162 |
| 2026-04-08 | Angermayer Christian |
Director, 10% Owner |
Convert↑
Filing footnotes — Common Stock (Direct)
Represents shares acquired upon exercise of options and held by the Reporting Person. |
Common Stock
|
46,070 |
| 2026-04-08 | Angermayer Christian |
Director, 10% Owner |
Convert↓
Filing footnotes — Stock Option (Direct)
The stock option is fully vested and exercisable. |
Stock Option
|
46,070 |
| 2026-03-20 | Craig Kevin James |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.52 to $3.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
Stock Option
|
23,776 |
| 2026-03-20 | Craig Kevin James |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
23,776 |
| 2026-03-20 | Craig Kevin James |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. |
Common Stock
|
76,224 |
| 2026-03-20 | Craig Kevin James |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Option (Direct)
The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |
Stock Option
|
76,224 |
| 2026-03-20 | Craig Kevin James |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. |
Common Stock
|
100,000 |
| 2026-03-11 | Faerm Michael E. |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on March 11, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
1,275,000 |
| 2026-03-11 | Faerm Michael E. |
Chief Financial Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
The restricted stock units vest (subject to continued service through each such vesting date) in four equal annual instalments on each of the first four anniversaries of March 11, 2026. |
Restricted Stock Units
|
285,000 |
| 2026-03-09 | Faerm Michael E. |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-01-30 | Kochendoerfer Gerd |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on January 1, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
675,000 |
| 2026-01-30 | Rao Srinivas |
See Remarks |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. |
Restricted Stock Units
|
442,000 |
| 2026-01-30 | Kochendoerfer Gerd |
Chief Operating Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. |
Restricted Stock Units
|
150,000 |
| 2026-01-30 | Johnson Anne Nagengast |
Chief Financial Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. |
Restricted Stock Units
|
117,000 |
| 2026-01-30 | Barrett Christopher Ryan Cave |
See Remarks |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on January 1, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
675,000 |
| 2026-01-30 | Craig Kevin James |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on January 1, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
675,000 |
| 2026-01-30 | Craig Kevin James |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. |
Restricted Stock Units
|
150,000 |
| 2026-01-30 | Rao Srinivas |
See Remarks |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on January 1, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
1,988,000 |
| 2026-01-30 | Short Glenn Frank |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on January 1, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. |
Stock Option
|
675,000 |